// Workers AI · dad joke modeWhat did Azaribine say to its friend? "You're a ribe-uting companion".
 | |
| Clinical data | |
|---|---|
| Trade names | Triazure |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.016.832 |
| Chemical and physical data | |
| Formula | C14H17N3O9 |
| Molar mass | 371.302 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Azaribine (triacetyl-6-azauridine) is a drug developed by Calbiochem for the treatment of psoriasis,[1][2] and also has anti-cancer and antiviral actvities.[3][4] It is a prodrug which is metabolised to the nucleoside analogue 6-azauridine in the body.[5]
Azaribine received FDA approval in 1975 for the treatment of severe psoriasis,[2][6][7] but was subsequently withdrawn from the market in 1976 (with its New Drug Application formally revoked in 1977[8]), following reports of life-threatening thromboembolic events.[2][5] These side effects, including both arterial and venous thrombosis, are primarily attributed to azaribine acting as a vitamin B6 antagonist, which induces a severe functional deficiency of pyridoxal phosphate and the resultant hyperhomocysteinemia.[5][9][10][11] However, it continues to be researched as a potential agent for the treatment of emerging viral diseases.[12]
References
[edit]- ↑ Elis J, Rasková H (March 1972). "New indications for 6-azauridine treatment in man. A review". European Journal of Clinical Pharmacology. 4 (2): 77–81. doi:10.1007/bf00562501. PMID 4570456. S2CID 11005976.
- 1 2 3 Shubin S (1979). "Triazure and public drug policies". Perspectives in Biology and Medicine. 22 (2 Pt 1): 185–204. PMID 582335. Retrieved 2026-04-06.
- ↑ Creasey WA, Fink ME, Handschumacher RE, Calabresi P (March 1963). "Clinical and pharmacological studies with 2',3',5'-triacetyl-6-azauridine". Cancer Research. 23: 444–453. PMID 14023746.
- ↑ Morrey JD, Smee DF, Sidwell RW, Tseng C (July 2002). "Identification of active antiviral compounds against a New York isolate of West Nile virus". Antiviral Research. 55 (1): 107–116. doi:10.1016/s0166-3542(02)00013-x. PMID 12076755.
- 1 2 3 Shupack JL, Grieco AJ, Epstein AM, Sansaricq C, Snyderman SE (September 1977). "Azaribine, homocystinemia, and thrombosis". Archives of Dermatology. 113 (9): 1301–1302. doi:10.1001/archderm.1977.01640090149047. PMID 578401.
- ↑ Crutcher WA, Moschella SL (February 1975). "Double-blind controlled crossover high-dose study of Azaribine in psoriasis". The British Journal of Dermatology. 92 (2): 199–205. doi:10.1111/j.1365-2133.1975.tb03059.x. PMID 1096923.
- ↑ McDonald CJ (1981). "The uses of systemic chemotherapeutic agents in psoriasis". Pharmacology & Therapeutics. 14 (1): 1–24. doi:10.1016/0163-7258(81)90008-5. PMID 7033998.
- ↑ "Federal Register, Volume 63 Issue 195 (Thursday, October 8, 1998)". GovInfo. 1998-10-08. Retrieved 2026-03-25.
- ↑ Gitel SN, Grieco AJ, Wessler S, Snyderman SE (1979). "The thrombogenicity of 6-azouridine". Haemostasis. 8 (1): 54–57. doi:10.1159/000214291. PMID 456945.
- ↑ Slavik M, Smith KJ, Blanc O (December 1982). "Decrease of serum pyridoxal phosphate levels and homocystinemia after administration of 6-azauridine triacetate and their prevention by administration of pyridoxine". Biochemical Pharmacology. 31 (24): 4089–4092. doi:10.1016/0006-2952(82)90664-5. PMID 6186258.
- ↑ Drell W, Welch AD (1989). "Azaribine-homocystinemia-thrombosis in historical perspective". Pharmacology & Therapeutics. 41 (1–2): 195–206. doi:10.1016/0163-7258(89)90106-X. PMID 2469090.
- ↑ Park JG, Ávila-Pérez G, Nogales A, Blanco-Lobo P, de la Torre JC, Martínez-Sobrido L (January 2020). "Identification and characterization of novel compounds with broad spectrum antiviral activity against influenza A and B viruses". Journal of Virology. 94 (7). doi:10.1128/JVI.02149-19. PMC 7081893. PMID 31941776.
 | This dermatologic drug article is a stub. You can help Wikipedia by adding missing information. |